Case Report
The Role of Benralizumab in Eosinophilic Immune Dysfunctions: A Case Report-Based Literature Review
Table 2
Changes in clinical parameters during the patient follow-up (2019–2022).
| | Main parameters | Before benralizumab (2019) | After benralizumab (to date) |
| | Eosinophils (cell/μL) | 290 | 0 | | Prednisolone (mg) | 20 | 5 | | ACT (points) | 19 | 23 | | CARAT (points) | 22 | 23 | | Mini-AQLQ (points) | 3 | 4.7 |
|
|
